Orthokeratology, Soft Multifocal Contact Lenses, and Atropine Therapy have been proven to slow down the progression of Myopia. High levels of myopia come with a 10x to 100x increased risk of sight threatening complications like Retinal Detachments, Glaucoma, and Myopic Macular Degeneration.
Are your child’s eyes getting worse every year?
Until recently, giving stronger glasses was the only option for correcting nearsightedness (myopia). Fortunately, the latest research is indicating that myopia in children can be slowed significantly with specialty treatments. Worsening myopia predisposes patients to greater risk of retinal detachment, glaucoma, and myopic macular degeneration. The higher the myopia the greater the risk of these conditions. There are three main ways to slow down the progression of myopia: Orthokeratology (Ortho K), Multifocal Soft Contact Lenses, or Atropine Therapy. Schedule an appointment so that we may customize an individualized treatment plan that works for you, your child, and your family.
Three treatments available for slowing down the progression of Myopia:
Orthokeratology (Ortho K)
Imagine being able to see clear all day without the hassle of glasses or contact lenses. This is possible with Orthokeratology. Ortho K is a non surgical treatment that corrects your vision by gently reshaping your eyes while you sleep. You wear the retainers over night. The next morning, you simply remove the retainers and experience clear vision all day.
Multifocal Contact Lenses
The MiSight daily disposable contact lenses are therapeutic contact lenses that are clinically proven and FDA approved to slow down the progression of Myopia. In a clinical study, children ages 8 to 12 years old showed a 59% reduction in the worsening of their vision compared to those not wearing the MiSight lenses.
Atropine drops are medicated prescription drops which widen the pupil and relax the eye muscles. In low concentrations, it has been shown to slow down the progression of myopia. A clinical study found that children aged 6 to 12 who received atropine experienced significantly less myopia progression.